Brief: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 For The Treatment Of Obesity
30/06/2025 13:13
Corbus Pharmaceuticals Holdings Inc CRBP.O: CORBUS PHARMACEUTICALS INITIATES MULTIPLE ASCENDING DOSE PORTION OF PHASE 1 STUDY OF HIGHLY PERIPHERALLY RESTRICTED CB1 INVERSE AGONIST CRB-913 FOR THE TREATMENT OF OBESITY CORBUS PHARMACEUTICALS HOLDINGS INC - MAD PORTION OF PHASE 1 TRIAL SCHEDULED FOR COMPLETION IN Q3 2025 CORBUS PHARMACEUTICALS HOLDINGS INC - PHASE 1B DOSE-RANGE FINDING STUDY EXPECTED TO COMMENCE IN Q4 2025 Source text: ID:nGNXc7RHnT Further company coverage: CRBP.O
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study